Anlon Healthcare Limited — Q2 FY26 earnings call

Call held 19 Nov 2025

Management summary

Anlon Healthcare reported strong Q2 and H1 FY26 financial performance, with significant revenue and PAT growth driven by operating leverage and improved business mix. The company is aggressively expanding capacity through a 700 metric ton greenfield facility and planned inorganic acquisitions, aiming for a total capacity of 1800-1900 metric tons and revenue of INR 520-540 crore by FY27/28. Anlon is focused on high-margin APIs, global market penetration, and expects to be debt-free by Q3 FY27, despite some pricing pressures in the API market.

Highlights

  • Q2 FY26 total income of INR 52.32 crore, up 116% YoY from INR 24.21 crore in Q2 FY25.

  • Q2 FY26 PAT of INR 9.32 crore, a nearly 4x jump from INR 2.59 crore in Q2 FY25, driven by strong operating leverage.

  • H1 FY26 total income of INR 85.53 crore, up 38% YoY from INR 62.11 crore, with PAT doubling to INR 12.86 crore.

  • Anvisa approval for manufacturing facility, reflecting adherence to global GMP standards, with 21 DMFs filed.

  • CDMO commercialization scheduled for Q3 FY27 with 3 molecules under development for 2 global innovator companies.

Concerns

  • API/intermediate prices reduced by 10-15% this year due to price war from China, though market is now stable.

  • Trade receivables of INR 20-30 crore are more than six months old, attributed to a distributor issue, but expected to be recovered by year-end.

Key financials

2 periods

Q2 FY26

  • Total Income
    ₹52.32 Cr
    YoY +116.1%
  • EBITDA
    ₹13.77 Cr
    YoY +81.9%
  • PAT
    ₹9.32 Cr
    YoY +260%

H1

  • FY26 Total Income
    ₹85.53 Cr
    YoY +37.7%
  • FY26 EBITDA
    ₹20.01 Cr
    YoY +37.5%
  • FY26 PAT
    ₹12.86 Cr
    YoY +102.2%

What they filed

Q1 FY27: revenue up 162.9%, net profit up 133.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue24 9 49 33 52 +116%36 +280%51 +4%88 +163%
EBITDA8 1 17 6 14 +83%12 +2017%15 −11%16 +150%
Net profit3 -2 17 4 9 +260%5 +307%11 −34%8 +133%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • H1 FY26 Product Mix
    70% API Contribution27.2% Intermediate Contribution

Order book

high confidence

Total value

₹380 Cr

as of 2025-09-30 quantified

Execution

for next year

Composition

  • Export (client type) 60%
Strong order visibility for next year's registered products, with a significant portion from exports.

Source: Q&A

Capital allocation

high confidence
  • Capex ₹32 Cr IPO proceeds and internal accruals, without any debt or bank loan
    • New capex expansion (700 metric ton greenfield facility) ₹32 Cr
    in DRHP, when we got the IPO proceed, we have reserved the 31 CR for the new capex expansion. So that fund we are having with us and right now we don't need to get any debt or bank loan for the further new expansion. For this specifically capex.
  • Debt Debt disclosed
    So right now the only debt is around 4.5 CR of the term loan. Otherwise, there is no any further outsider debt.
  • M&A Undisclosed Acquisition · Announced · Consideration ₹[object Object] (undisclosed)

    To increase API or finished product capacity in existing plant and not lose business opportunities due to current low capacity.

    Expected to add capacity of more than 1,100 metric tons and contribute maximum 300 CR in peak revenue from current planned products.

    CapEx we are planning for at least 32 CR for the expansion. And if we are going for some inorganic acquisition, then it would be around 50 to 55 CR. ... Yeah, 50 to 55 CR. Uh, oh, (in Hindi). That will be more than total 1,100 metric ton. So that is what we require t- Understood. It will be more than that.
  • Liquidity Liquidity disclosed IPO proceeds and reserve surplus available to fund expansion and acquisition.
    We have the right now case with us from the IPO proceed and reserve surplus also, so we are not planning for any debt as of now. Debt we'll buy it from our own fund.

Guidance & targets

Revenue

  • Revenue CAGR Revenue · next three years · High confidence 30%+
    This expansion will support our ambition to achieve a 30% plus revenue CAGR over the next three years, alongside a structurally improving margin profile.

    — Punit Kumar Rasadia, Chairman & Managing Director

  • Peak Revenue from Existing Facility Revenue · this year · High confidence 170 to 180 CR
    I think this year we are expecting somewhere around 170 to 180 CR from the existing facility at the peak.

    — Punit Kumar Rasadia, Chairman & Managing Director

  • Peak Revenue from Total 1100 MT Capacity Revenue · after 1100 metric ton total capacity · High confidence 360 to 400 CR
    At that time, we are expecting the peak revenue somewhere around 360 to 400 CR.

    — Punit Kumar Rasadia, Chairman & Managing Director

  • Revenue after Inorganic Acquisition Revenue · next year (FY27) · High confidence minimum 360 to 400 CR
    Next year, honestly, we are expecting minimum 360 to 400 CR after inorganic acquisition.

    — Punit Kumar Rasadia, Chairman & Managing Director

  • Average Revenue from All Three Facilities Revenue · FY27/28 · Medium confidence 520 to 540 CR
    I can tell you the average what we are expecting right now would be after all three commencement and everything would be somewhere between 520 to 540 CR.

    — Punit Kumar Rasadia, Chairman & Managing Director

Capacity

  • Total Capacity Capacity · after greenfield expansion · High confidence 1100 metric ton/year
    executing our 700 metric ton a year greenfield expansion, which will take our total capacity to 1100 metric ton a year.

    — Punit Kumar Rasadia, Chairman & Managing Director

CDMO

  • CDMO Commercialization CDMO · Q3 FY27 · High confidence Commercialization scheduled
    Commercialization is scheduled for Q3 FY '27, marking Anlon's entry into the high-value global CDMO space.

    — Punit Kumar Rasadia, Chairman & Managing Director

Product Launch

  • High-Value Molecules Launch Product Launch · third quarter of next year (Q3 FY27) · High confidence Launch
    Uh, third quarter of next year. Validation is already completed. Three months stability data is pending from customer end, so all this procedure and registration will take at least six months. So, we are expecting by third quarter of next year.

    — Punit Kumar Rasadia, Chairman & Managing Director

Export

  • Export Revenue Share Export · this financial year (FY26) · High confidence 30%
    But this year I think we'll close with somewhere around 30% export in this financial year.

    — Punit Kumar Rasadia, Chairman & Managing Director

  • Export Revenue Share Export · next financial year (FY27) · High confidence 60%
    Next year, see, considering the current order and all these registrations and approval, all those thing, we are confident to make the at least 60% of export revenue for next financial year.

    — Punit Kumar Rasadia, Chairman & Managing Director

Profitability

  • EBITDA Margin Profitability · future · High confidence 25%+
    our EBITDA margin will not be less than the 25%.

    — Punit Kumar Rasadia, Chairman & Managing Director

Debt

  • Debt-Free Status Debt · Q3 FY27 · High confidence Debt-free
    We are planning that by last quarter of next calendar year, means third quarter of next financial year, we will be the debt-free.

    — Punit Kumar Rasadia, Chairman & Managing Director

What to watch in Q3 FY26

Inorganic Acquisition Finalization

next quarter
Current Actively looking, outcome expected within this month or mid-next month.
Target Acquisition announced/finalized.

Why it matters

The acquisition is crucial for immediate capacity expansion and achieving revenue growth targets, especially given current capacity constraints.

We are already looking for that and we have identified some facilities also. ... maybe within this month or mostly by mid of next month, we'll come with some outcome and finalizes on the acquisition.

Risks & concerns

  • API/Intermediate Price War

    medium

    API and intermediate prices reduced by 10-15% this year due to price war from China, though management states the market is now stable.

    Management acknowledged

  • High Trade Receivables

    low

    INR 20-30 crore of trade receivables are more than six months old due to a distributor issue, but management expects full recovery by year-end.

    Management acknowledged

  • Customer Concentration

    low

    Significant contribution from top five customers, but management explains this is typical for the API business with high entry barriers and that they serve over 125 domestic customers indirectly.

    Analyst downplayed

Q&A highlights

7 direct
700 MT Greenfield Plant Timeline and Revenue Potential Direct
The commissioning will start immediately within this quarter and it will take around 16 to 18 month for the completion. ... At that time, we are expecting the peak revenue somewhere around 360 to 400 CR.

Clarifies the timeline for the major capacity expansion and provides the peak revenue expectation from the combined 1100 MT capacity.

Asked by Paras Cheda

Capex Funding and Debt Reduction Strategy Direct
in DRHP, when we got the IPO proceed, we have reserved the 31 CR for the new capex expansion. So that fund we are having with us and right now we don't need to get any debt or bank loan for the further new expansion. ... We are planning that by last quarter of next calendar year, means third quarter of next financial year, we will be the debt-free.

Details the funding sources for expansion and acquisition (internal accruals) and sets a clear target for becoming debt-free, indicating financial prudence.

Asked by Bhavesh Patel

Discrepancy in Capacity vs. Revenue Growth Projections Partial
Because we are expecting around 16 to 18 months for the completion of the expansion. And we'll hardly get six to seven months in finance area. So that's why that revenue what we are proposing you, that is considering six, seven months revenue after expansion. ... we are considering our backward integrated raw material, or KSM, which is not required regulatory registration, that we are planning to manufacture over there.

Explains the phased revenue contribution due to the long completion timeline and the strategic use of new capacity for lower-value intermediates to optimize existing API production.

Asked by Rudraksh Raheja

Export Strategy and Margin Differential Direct
this year I think we'll close with somewhere around 30% export in this financial year. ... there is a difference between 15 to 17% between domestic and export.

Highlights the company's aggressive export growth targets and the significant margin advantage in export markets, which will drive future profitability.

Asked by Rudraksh Raheja

Explanation for FY24 Revenue Drop Direct
Actually what happened, in 2022, we filed the DMF in Brazil. ... we have to take the mandatory shutdown of the four months, so that stops our sales and it reflects in the FY24 results, so that's why the sales was down.

Provides a clear, non-recurring reason for a past financial underperformance, reassuring investors about the underlying business health.

Asked by Paris

Inorganic Acquisition Status and Rationale Direct
We are already looking for that and we have identified some facilities also. ... If we will not supply to our customer, then maybe there is a possibility that they will start to identify the new supplier. So we don't want to lose the business opportunity.

Confirms active pursuit of acquisitions to mitigate capacity constraints and retain customer business, indicating proactive management of growth opportunities.

Asked by Bhavesh Patel

Product Selection Criteria and China Dependency Direct
we are very good in some kind of specific methylation and Friedel-Crafts chemistry. ... we are selecting some molecules in which there should not be any Chinese dependency, along with there is a possibility to become the world's largest in specific molecule.

Outlines the strategic approach to product development, focusing on specialized chemistry and reducing supply chain risks by avoiding China dependency.

Asked by Rudraksh Raheja

US and EU Regulatory Approval Timelines Direct
we have not applied for the US purposefully because we are supplying one of our product to Sanofi, Germany. Right. And Sanofi is going to trigger USFDA audit in June 26. ... EU, we already applied the EDQM. We already got the confirmation from them. ... by the end of this year, we'll be most likely EU compliant also.

Provides clarity on the company's strategy for entering regulated markets, leveraging customer relationships for USFDA approval and expecting EU compliance soon.

Asked by Paris

3 min read 7 chapters

Detailed narrative

Robust Financial Performance in Q2 and H1 FY26

Anlon Healthcare demonstrated strong financial growth in Q2 FY26, with total income reaching INR 52.32 crore, marking a 116% year-on-year increase from INR 24.21 crore in Q2 FY25. EBITDA for the quarter grew 82% to INR 13.77 crore, and PAT surged nearly fourfold to INR 9.32 crore. For the first half of FY26, total income rose 38% to INR 85.53 crore, and PAT more than doubled to INR 12.86 crore, driven by consistent contribution from high-value intermediates and APIs.

Aggressive Capacity Expansion and Inorganic Growth Strategy

The company is pursuing a significant capacity expansion plan, including a 700 metric ton per year greenfield facility, which will increase total capacity to 1100 metric tons. Commissioning for this facility is set to begin within the current quarter and is expected to be completed in 16-18 months. Additionally, Anlon is actively exploring inorganic acquisitions, with an outcome anticipated by mid-next month, to further boost capacity by over 1100 metric tons and capitalize on existing order visibility.

Strategic Focus on High-Margin APIs and Global Market Penetration

Anlon aims to achieve a 30%+ revenue CAGR over the next three years by expanding into global markets and strengthening its portfolio of high-margin APIs. The company has secured Anvisa approval for its manufacturing facility, filed 21 DMFs, and plans upcoming submissions for ketoprofen in the USA and dexketoprofen trometamol in European countries. Commercialization of CDMO projects is scheduled for Q3 FY27, marking the company's entry into the high-value global CDMO space.

Prudent Funding and Debt-Free Ambition

The planned capital expenditure for the 700 metric ton expansion (INR 32 crore for FY27) and the inorganic acquisition (INR 50-55 crore) will be entirely funded through IPO proceeds and internal accruals, with no new debt planned. Management stated a clear objective to become debt-free by Q3 FY27, with current term loan debt standing at approximately INR 4.5 crore, demonstrating a commitment to a strong financial position.

Evolving Product Mix and Enhanced Export Focus

While H1 FY26 saw a product mix of approximately 70% APIs and 27.2% intermediates, the company is strategically adjusting its portfolio. Anlon is targeting to close FY26 with around 30% export revenue, with an ambitious goal to increase this to 60% in FY27. This export push is driven by a significant margin advantage, with export products yielding 15-17% higher EBITDA margins compared to domestic sales.

Operational Efficiency and Supply Chain Resilience

The Rajkot manufacturing facility operates at 84% capacity utilization, supported by a strong quality system and in-house R&D. Anlon maintains a fully backward integrated supply chain, with no direct KSM imports from China, primarily sourcing solvents and reagents from domestic importers. This strategy, coupled with continuous process optimization, aims to reduce dependency risks and enhance competitiveness.

Long-Term Revenue Outlook and Regulatory Compliance

With the full operationalization of its existing facility, new greenfield expansion, and inorganic acquisition, Anlon projects a total capacity of 1800-1900 metric tons. The company anticipates achieving an average revenue of INR 520-540 crore by FY27/28. Anlon is also progressing on regulatory fronts, expecting EU compliance by the end of this year and leveraging a customer to trigger a USFDA audit in June 2026.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls